Skip to content
Research Article Open access CC BY 4.0

Epidemiology, Treatment and Microbiological Surveillance of SARS-CoV-2

Manikant Tripathi, Shailendra Kumar

Annual Research & Review in Biology · pp. 114–121 · Published 26 Jun 2020

10.9734/arrb/2020/v35i530230

Abstract

Coronaviruses (CoV) belong to Coronaviridiae family that cause deadly diseases in humans or animals. These viruses are enveloped and have single stranded positive-sense large RNA genome. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) causes deadly pandemic coronavirus disease-2019 (COVID-19) in humans. It is affecting every aspect of humans’ daily life. The symptoms of COVID-19 include fever, loss of smell, shortness of breath, cough, muscles pain, chest pain, and kidney failure that occurs in severe conditions. The virus has spread throughout the world.  In India, the estimated number of infected people is more than 1.5 lakh with less fatality rate 2.87% on May 27, 2020 as per the Ministry of Health and Family Welfare data. The studies suggest that virus has been considered descended from the previous viruses as severe acute respiratory syndrome corona virus (SARS-CoV), Middle East respiratory syndrome virus (MERS) human and bat corona viruses. Currently, vaccine developments are under clinical trials. The management of emerging infectious diseases is a challenging task. It requires much improved microbiological surveillance system to track and predict the virus infections. The proper study and predictions based on screening of various sources of infection may help us to manage the challenging infections in future. The present review summarizes the characteristics of virus, disease symptoms, epidemiology, transmission, treatment and microbiological surveillance of pandemic COVID-19.

Coronavirus COVID-19 microbiological surveillance pandemic SARS-CoV-2

References (29)

  1. 1 A pneumonia outbreak associated with a new coronavirus of probable bat origin [DOI]
  2. 2 The global burden of women’s cancers: a grand challenge in global health [DOI]
  3. 3 Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding [DOI]
  4. 4 Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 [DOI]
  5. 5 Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents [DOI]
  6. 6 Features, Evaluation and Treatment Coronavirus (COVID-19)
  7. 7 Emerging coronaviruses: Genome structure, replication, and pathogenesis [DOI]
  8. 8 Coronavirus Infections—More Than Just the Common Cold [DOI]
  9. 9 The COVID-19 vaccine development landscape [DOI]
  10. 10 Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion [DOI]
  11. 11 The Effects of Temperature and Relative Humidity on the Viability of the SARS Coronavirus [DOI]
  12. 12 Laboratory diagnosis of emerging human coronavirus infections – the state of the art [DOI]
  13. 13 SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview
  14. 14 Candidate drugs against SARS-CoV-2 and COVID-19 [DOI]
  15. 15 2019 Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature [DOI]
  16. 16 Supramolecular Architecture of Severe Acute Respiratory Syndrome Coronavirus Revealed by Electron Cryomicroscopy [DOI]
  17. 17 Outbreak of a novel coronavirus [DOI]
  18. 18 Effective inhibition of MERS-CoV infection by resveratrol [DOI]
  19. 19 Molecular pathology of emerging coronavirus infections [DOI]
  20. 20 A Review of COVID-19 (Coronavirus Disease-2019) Diagnosis, Treatments and Prevention [DOI]
  21. 21 Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M pro ) of SARS-CoV-2 and inhibit its activity [DOI]
  22. 22 Coronaviridae [DOI]
  23. 23 Lysosomal Proteases Are a Determinant of Coronavirus Tropism [DOI]
  24. 24 Cytokine-targeted therapy in severely ill COVID-19 patients: Options and cautions [DOI]
  25. 25 Laboratory preparedness for SARS-CoV-2 testing in India [DOI]
  26. 26 Biorisk assessment for infrastructure & biosafety requirements for the laboratories providing coronavirus SARS-CoV-2/(COVID-19) diagnosis [DOI]
  27. 27 Genome Organization of Covid-19 and Emerging Severe Acute Respiratory Syndrome Covid-19 Outbreak: A Pandemic [DOI]
  28. 28 Novel Coronavirus Disease ( COVID-19) Pandemic in India: A Review [DOI]
  29. 29 ACE 2 in the Context of COVID 19 – An Opportunity for us or the Virus [DOI]

Cited by 3

The Use of Artificial Intelligence in New Normal Era Against Pandemic COVID-19 in the Field of Health Services

Dian Agustin Wahjuningrum, Fery Setiawan, Setyabudi · Conservative Dentistry Journal · 2022

Showing 1 of 3 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

81

Page views

0

PDF downloads

82

Outbound clicks

3

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.